共 50 条
- [1] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Cheng, A.Kang, Y.Chen, Z.Tsao, C.Qin, S.Kim, J.Burock, K.Zou, J.Voliotis, D.Guan, Z. Z.
- [2] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)Cainap, CalinQin, ShukuiHuang, Wen-TsungChung, Ik-JooPan, HongmingCheng, YingKudo, MasatoshiKang, Yoon-KooChen, Pei-JerToh, Han ChongGorbunova, VeraEskens, FerryQian, JiangMcKee, Mark D.Ricker, Justin L.Carlson, Dawn M.El Nowiem, Saied
- [3] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III TrialJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77Cainap, CalinQin, ShukuiHuang, Wen-TsungChung, Ik JooPan, HongmingCheng, YingKudo, MasatoshiKang, Yoon-KooChen, Pei-JerToh, Han-ChongGorbunova, VeraEskens, Ferry A. L. M.Qian, JiangMcKee, Mark D.Ricker, Justin L.Carlson, Dawn M.El-Nowiem, Saied
- [4] Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Cheng, A.Kang, Y.Lin, D.Park, J.Kudo, M.Qin, S.Omata, M.Lowenthal, S. W. PitmanLanzalone, S.Yang, L.Lechuga, M.Raymond, E.
- [5] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Abou-Alfa, Ghassan K.Niedzwieski, DonnaKnox, Jennifer J.Kaubisch, AndreasPosey, JamesTan, Benjamin R.Kavan, PetrGoel, RakeshLammers, Philip EdwardBekaii-Saab, Tanios S.Tam, Vincent ChanningRajdev, LakshmiKelley, Robin KateSiegel, Abby B.Balletti, JenniferHarding, James J.Howard, Lawrence SchwartzGoldberg, Richard M.Bertagnolli, Monica M.Venook, Alan P.
- [6] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Abou-Alfa, Ghassan K.Niedzwieski, DonnaKnox, Jennifer J.Kaubisch, AndreasPosey, JamesTan, Benjamin R.Kavan, PetrGoel, RakeshMurray, John J.Bekaii-Saab, Tanios S.Tam, Vincent ChanningRajdev, LakshmiKelley, Robin KateSiegel, AbbyBalletti, JenniferHarding, James J.Schwartz, Lawrence HowardGoldberg, Richard M.Bertagnolli, Monica M.Venook, Alan P.
- [7] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Palmer, Daniel H.Ma, Yuk TingPeck-Radosavljevic, MarkusRoss, Paul J.Graham, Janet ShirleyFartoux, LaetitiaDeptala, AndrzejWenz, ArneHocke, JuliaLoembe, Arsene-BienvenuMeyer, Tim
- [8] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Cheng, Ann-LiiYen, Chia-JuiKim, Tae-YouFeng, Yin-HsunChao, YeeLin, Deng-YnLoembe, Arsene-BienvenuHocke, JuliaChoi, CarenRyoo, Baek-Yeol
- [9] Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepatocellular carcinoma (HCC)JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Dumas, F.Barbare, J.Aparicio, T.Bouche, O.Lombard-Bohas, C.Faroux, R.Seitz, J.Raoul, J.Bedenne, L.Bonnetain, F.
- [10] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)Abou-Alfa, Ghassan K.Meyer, TimCheng, Ann-LiiEl-Khoueiry, Anthony B.Rimassa, LorenzaRyoo, Baek-YeolCicin, IrfanMerle, PhilippePark, Joong-WonBlanc, Jean-FredericBolondi, LuigiKlumpen, Heinz JosefChan, Stephen LamDadduzio, VincenzoHessel, ColinBorgman-Hagey, Anne E.Schwab, GiselaKelley, Robin Kate